Clinical Investigation Shows Herb-Pharma's ViroStop Spray Effective in Reducing Impact of Covid-19
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
Dr István Jankovics, whose team ran the study commented, "The primary treatment for Covid 19 is, of course, vaccination, however this study means that the use of the ViroStop spray significantly inhibits the amount of SARS CoV-2 in the upper respiratory tract, thus providing an opportunity for the infected person to develop a specific immune response."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
ZURICH -- Businesswire -- A recent clinical study has shown that the ViroStop anti-viral spray from Swiss company, Herb-Pharma is effective in reducing the impact of Covid-19 for patients with mild to moderate symptoms.
The key benefits were a 60% reduction in viral shedding after using the treatment and a reduction in the severity of clinical respiratory symptoms. The study supports the findings of earlier in-vitro tests where its mix of polyphenols inhibited the growth of the virus in cell cultures.
The study included 170 PCR confirmed SARS-CoV-2 patients at the Complex Medical Clinic in Budapest, Hungary between January 15th, and May 31st, 2021. The volunteers all had mild to moderate respiratory symptoms, having tested positive in PCR tests for Covid-19 at the start of the study, and their symptoms were monitored over 12 days.
Of the 170 volunteers, 86 received a nasopharyngeal spray, the patented ViroStop solution, which contains a mixture of Cistus Creticus and other polyphenol-rich ingredients. Polyphenols when attached to viral protein, mechanically inhibit the workings of the protein, and thus stop the virus from entering the cell. The rest of the 84 patients remained in the control group and were not given the ViroStop solution. Each patient’s symptoms were checked every two days for 12 days.
At the end of the study the level of viral shedding was checked by PCR tests. Those patients who had used the ViroStop spray from the first day after testing positive, showed an almost 60% reduction in viral shedding on day 12, compared to the control group. The study showed that the severity of respiratory clinical symptoms was also reduced in those who used ViroStop spray.
A reduction was also noted in gastrointestinal symptoms compared to the control group. Recent research has shown that a key factor in the spread of the virus is its ability to also multiply in the gastrointestinal tract.
Dr István Jankovics, whose team ran the study commented, “The primary treatment for Covid 19 is, of course, vaccination, however this study means that the use of the ViroStop spray significantly inhibits the amount of SARS CoV-2 in the upper respiratory tract, thus providing an opportunity for the infected person to develop a specific immune response.”
ViroStop is a non-prescription treatment, made from natural ingredients and can be taken safely by children as young as three. Furthermore, at the time of the study, at least three variants of the virus were present in Hungary, so it is reasonable to assume that the solution and the action of polyphenols is effective against all known mutations of Covid-19.
Issued on behalf of:
Herb-Pharma AG Waldmannstrasse 6, 8001 Zurich, Switzerland
Company email: home@herb-pharma.com For more information visit: https://www.virostop.info/ Company website: https://www.fytofontana.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005309/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Herb-Pharma
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- SK네트웍스, 대규모 자기주식 소각… 주주가치 제고 정책 강화 - 뉴스와이어
- 서울시광역심리지원센터, 2026년 ‘마음안심버스’ 운영 본격화 - 뉴스와이어
- 동구바이오제약, 지놈앤컴퍼니에 추가 투자… 신규 타깃 항체·ADC 신약 개발 전환에 전략적 참여
- 우주산업, KOREA PACK 2026에서 혁신적인 전자동 열성형 포장 기술 선보여 - 뉴스와이어
- 셀레브레인 ‘CB11’, 미국 FDA 희귀의약품 지정… 악성 신경교종 치료제 개발 가속 - 뉴스와이어
- 우리가 매운맛에 열광하는 이유도 유전자 때문일까… 과학자가 전하는 생물학의 뒷이야기 - 뉴
- BC카드, 일본 au PAY와 결제 연동으로 가맹점 매출 지원 나서 - 뉴스와이어
- 바디프랜드, 마사지 모드 구독 서비스 관련 특허 등록 - 뉴스와이어
- 해운대나눔과행복병원, 회복기 재활의료기관 ‘스마트 병동’ 선도… 대웅제약과 ‘씽크’ 도
- SICK코리아, RTLS 트렌드와 산업 적용 사례 공유… 현장 데모 세미나 성료 - 뉴스와이어